Sign In
Buy PBYI
$6.81
-0.170 (-2.44%)
At Close: Jun 03, 2026
Puma Bio: Still Worthy Of Consideration After Earnings Surprise
04:54am, Tuesday, 08'th Mar 2022 Seeking Alpha
Puma Biotech (PBYI) Q4 Earnings Beat Mark, Revenues Rise Y/Y
06:19pm, Friday, 04'th Mar 2022 Zacks Investment Research
Puma Biotechnology (PBYI) beats on earnings and sales for the fourth quarter of 2021. PBYI???s shares increase in after-market trading session following the news.
Puma Biotech (PBYI) Q4 Earnings Beat Mark, Revenues Rise Y/Y
02:34pm, Friday, 04'th Mar 2022
Puma Biotechnology (PBYI) beats on earnings and sales for the fourth quarter of 2021. PBYI???s shares increase in after-market trading session following the news.
Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach On Q4 2021 Results - Earnings Call Transcript
12:08am, Friday, 04'th Mar 2022 Seeking Alpha
Puma Biotech (PBYI) Q4 Earnings and Revenues Surpass Estimates
11:05pm, Thursday, 03'rd Mar 2022 Zacks Investment Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 190.91% and 16.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ZNGA, KPTI and PBYI among after hour movers
11:01pm, Thursday, 03'rd Mar 2022 Seeking Alpha
Gainers: Funko FNKO +16%. Puma Biotechnology PBYI +15%
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI)
10:27pm, Thursday, 03'rd Mar 2022 Seeking Alpha
Shares of Puma Biotechnology (PBYI) have raced 15% higher in post-market trading after posting Q4 2021 results that beat on the top and bottom lines.
Puma Biotechnology Non-GAAP EPS of $0.21 beats by $0.20, revenue of $55.4M beats by $8.23M
09:11pm, Thursday, 03'rd Mar 2022 Seeking Alpha
Puma Biotechnology press release (PBYI): Q4 Non-GAAP EPS of $0.21 beats by $0.20.Revenue of $55.4M (+5.3% Y/Y) beats by $8.23M.Cash, equivalents, and marketable securities of…
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
09:05pm, Thursday, 03'rd Mar 2022 Business Wire
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology issued financial results for the fourth quarter and year ended Dec. 31, 2021, followed by a call to discuss operating results.
The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO
12:46pm, Thursday, 03'rd Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis
NuCana plc (NASDAQ: NCNA) s
Will Puma Biotech (PBYI) Report Negative Q4 Earnings? What You Should Know
08:02pm, Thursday, 17'th Feb 2022 Zacks Investment Research
Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results
09:15pm, Wednesday, 16'th Feb 2022 Business Wire
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call at 1:30 pm PST on March 3 to review its fourth quarter and full year 2021 financial results.
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results
04:15pm, Wednesday, 16'th Feb 2022
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call at 1:30 pm PST on March 3 to review its fourth quarter and full year 2021 financial results.
Puma Biotechnology reports inducement awards under Nasdaq listing rule
10:36pm, Thursday, 03'rd Feb 2022 Seeking Alpha
Puma Biotechnology (PBYI) has announced that the Compensation Committee of Pumas Board approved the grant of inducement restricted stock unit awards covering an aggregate of 24,375
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates
10:15pm, Thursday, 27'th Jan 2022 Zacks Investment Research
Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -26.87% and 50.67%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the
